Selected Arylpiperazines Are Capable of Reversing Multidrug Resistance in Escherichia Coli Overexpressing RND Efflux Pumps

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2005 Jan 28

PMID 15673787

Citations 87

Authors

Jurgen A Bohnert

Winfried V Kern

Affiliations

Soon will be listed here.

Abstract

Several arylpiperazines capable of reversing multidrug resistance (MDR) in Escherichia coli overexpressing acrAB and acrEF but not in pump-deficient mutant strains were identified. 1-(1-Naphthylmethyl)-piperazine, one of the more active compounds, enhanced susceptibility to fluoroquinolones and other agents and increased the intracellular concentration of levofloxacin and ethidium bromide, suggesting efflux pump inhibition as the mechanism of MDR reversal.

Citing Articles

Tackling the outer membrane: facilitating compound entry into Gram-negative bacterial pathogens.

Saxena D, Maitra R, Bormon R, Czekanska M, Meiers J, Titz A NPJ Antimicrob Resist. 2025; 1(1):17.

PMID: 39843585 PMC: 11721184. DOI: 10.1038/s44259-023-00016-1.

Biofilm formation and polar lipid biosynthesis in Mycobacterium abscessus are inhibited by naphthylmethylpiperazine.

Faboro T, Daniel J PLoS One. 2024; 19(11):e0311669.

PMID: 39531471 PMC: 11556751. DOI: 10.1371/journal.pone.0311669.

Structural and functional diversity of Resistance-Nodulation-Division (RND) efflux pump transporters with implications for antimicrobial resistance.

Kavanaugh L, Dey D, Shafer W, Conn G Microbiol Mol Biol Rev. 2024; 88(3):e0008923.

PMID: 39235227 PMC: 11426026. DOI: 10.1128/mmbr.00089-23.

Extending the Potency and Lifespan of Antibiotics: Inhibitors of Gram-Negative Bacterial Efflux Pumps.

Duffey M, Jumde R, da Costa R, Ropponen H, Blasco B, Piddock L ACS Infect Dis. 2024; 10(5):1458-1482.

PMID: 38661541 PMC: 11091901. DOI: 10.1021/acsinfecdis.4c00091.

Types and Mechanisms of Efflux Pump Systems and the Potential of Efflux Pump Inhibitors in the Restoration of Antimicrobial Susceptibility, with a Special Reference to .

Zack K, Sorenson T, Joshi S Pathogens. 2024; 13(3).

PMID: 38535540 PMC: 10974122. DOI: 10.3390/pathogens13030197.

References

Renau T, Leger R, Flamme E, Sangalang J, She M, Yen R . Inhibitors of efflux pumps in Pseudomonas aeruginosa potentiate the activity of the fluoroquinolone antibacterial levofloxacin. J Med Chem. 1999; 42(24):4928-31. DOI: 10.1021/jm9904598. View

Kern W, Oethinger M, Jellen-Ritter A, Levy S . Non-target gene mutations in the development of fluoroquinolone resistance in Escherichia coli. Antimicrob Agents Chemother. 2000; 44(4):814-20. PMC: 89776. DOI: 10.1128/AAC.44.4.814-820.2000. View

Lomovskaya O, Warren M, Lee A, Galazzo J, Fronko R, Lee M . Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy. Antimicrob Agents Chemother. 2000; 45(1):105-16. PMC: 90247. DOI: 10.1128/AAC.45.1.105-116.2001. View

Sulavik M, Houseweart C, Cramer C, Jiwani N, Murgolo N, Greene J . Antibiotic susceptibility profiles of Escherichia coli strains lacking multidrug efflux pump genes. Antimicrob Agents Chemother. 2001; 45(4):1126-36. PMC: 90435. DOI: 10.1128/AAC.45.4.1126-1136.2001. View

Li X, Nikaido H . Efflux-mediated drug resistance in bacteria. Drugs. 2004; 64(2):159-204. DOI: 10.2165/00003495-200464020-00004. View